Treatment of opioid-dependent adolescents and young adults with buprenorphine

Current Psychiatry Reports

Volumn 11, Issue 5, 2009, Pages 360-363

  Subramaniam, Geetha A ^a   Fishman, Marc J ^a   Woody, George ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CLONIDINE; DIAMORPHINE; METHADONE; NALOXONE; NALTREXONE; OPIATE;

ADOLESCENT; ADULT; BEHAVIOR THERAPY; CLINICAL TRIAL; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG DETOXIFICATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LOW DRUG DOSE; MENTAL DISEASE; OPIATE ADDICTION; PSYCHOSOCIAL CARE; REVIEW; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; BUPRENORPHINE; CLINICAL TRIALS AS TOPIC; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; YOUNG ADULT;

EID: 70349745513     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-009-0054-5     Document Type: Review

References (25)

1. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE: Monitoring the Future: National Survey Results on Adolescent Drug Use: 1975-2006: Volume I, Secondary School Students. Bethesda, MD: National Institute on Drug Abuse; 2007 [NIH publication no. 07-6205.]
2. Substance Abuse and Mental Health Services Administration Office of Applied Studies: Drug Abuse Warning Network, 2006: National Estimates of Drug-related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Services Administration Office of Applied Studies: Drug Abuse Warning Network, 2006; 2008 [DAWN Series D-30, DHHS publication no. (SMA) 08-4339.] http://dawninfo.samhsa.gov/files/ED2006/ DAWN2k6ED.pdf.
3. Substance Abuse and Mental Health Services Administration: Adapted by CESAR from Substance Abuse & Mental Health Data Archive (SAMHDA): Online analysis of the concatenated 1992-2004 TEDS data set, 2008. Available at http://www.icpsr.umich.edu/SAMHDA/. Accessed November 15, 2006.
4. Centers for Disease Control and Prevention: Viral hepatitis and injection drug users. Available at http://www.cdc.gov/IDU/hepatitis/ viral_hep_drug_use.htm. Accessed September 15, 2007.
5. Ochoa KC, Hahn JA, Seal KH, Moss AR: Overdosing among young injection drug users in San Francisco. Addict Behav 2001, 26: 453-460.
6. Substance Abuse and Mental Health Services Administration Office of Applied Studies: Treatment Episode Data Set (TEDS): 1995-2005. National Admissions to Substance Abuse Treatment Services. Rockville, MD: Substance Abuse and Mental Health Services Administration Office of Applied Studies; 2007 [DASIS series: S-37, DHHS publication no. (SMA) 07-4234.]
7. Hopfer CJ, Mikulich SK, Crowley TJ: Heroin use among adolescents in treatment for substance use disorders. J Am Acad Child Adolesc Psychiatry 2000, 39: 1316-1323.
8. Clemmey P, Payne L, Fishman M: Clinical characteristics and treatment outcomes of adolescent heroin users. J Psychoactive Drugs 2004, 36: 85-94.
9. Gordon SM, Mulvaney F, Rowan A: Characteristics of adolescents in residential treatment for heroin dependence. Am J Drug Alcohol Abuse 2004, 30: 593-603.
10. Marsch LA, Bickel WK, Badger GJ, et al.: Comparison of pharmacological treatments for opioid-dependent adolescents: A randomized controlled trial. Arch Gen Psychiatry 2005, 62: 1157-1164.
11. Subramaniam GA, Stitzer MA, Woody GE, et al.: Clinical characteristics of treatment seeking adolescents with opioid versus cannabis/alcohol use disorders. Drug Alcohol Depend 2009, 99: 141-149.
12. Woody G, Poole S, Subramaniam GA, et al.: Extended medication-assisted therapy produces better outcomes than detoxification among opioid-addicted youth. JAMA 2008, 300: 2003-2011.
13. Substance Abuse and Mental Health Services Administration Office of Applied Studies: Treatment episode data set, 1992-2006 (concatenated). Rockville, MD: Substance Abuse and Mental Health Services Administration Office of Applied Studies; 2008. Available at http://www.icpsr.umich.edu/ cgi-bin/SDA/SAMHDA/hsda?samhda+tedsconcat. Accessed May 19, 2008.
14. Hopfer CJ, Khuri A, Crowley TJ, Hooks S: Adolescent heroin use: a review of the descriptive and treatment literature. J Subst Abuse Treat 2002, 23: 231-237.
15. Mattick RP, Breen C, Kimber J, Davoli M: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003: CD002209.
16. Mattick RP, Kimber J, Breen C, Davoli M: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008: CD002207.
17. Amato L, Davoli M, Perucci CA, et al.: An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. J Subst Abuse Treat 2005, 28: 321-329.
18. Parrino M: State Methadone Treatment Guidelines, Treatment Improvement Protocol (TIP) Series 1. Rockville, MD: Substance Abuse and Mental Health Services Administration; 1993 [DHHS publication no. (SMA) 93-1991.]
19. Substance Abuse and Mental Health Services Administration: Buprenorphine: The Drug Addiction Treatment Act of 2000 (DATA 2000). Available at http://buprenorphine.samhsa.gov/index.html. Accessed May 5, 2009.
20. Fudala PJ, Bridge TP, Herbert S, et al.: Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003, 349: 949-958.
21. Walsh SL, Preston KL, Stitzer ML, et al.: Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin Pharmacol Ther 1994, 55: 569-580.
22. US Food and Drug Administration: NDA 20-732. NDA 20-733. Available at http://www.fda.gov/cder/foi/label/2002/20732lbl.pdf. Accessed May 5, 2009.
23. Alho H, Sinclair D, Vuori E, Holopainen A: Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007, 88: 75-78.
24. New York Academy of Medicine: Physician Clinical Support System (PCSS)-buprenorphine: An educational resource for those treating patients with opioid dependence. 2005. Available at http://www.pcssbuprenorphine.org/. Accessed May 6, 2009.
25. Comer SD, Sullivan MA, Yu E, et al.: Injectable, sustainedrelease naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial. Arch Gen Psychiatry 2006, 62: 210-218.